NCT00784836View on ClinicalTrials.gov

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Multiple Sclerosis
Interventions
DRUG

BG9418 (interferon beta 1-a)

Trial Locations (2)

48202

Henry Ford Hospital, Detroit

75214

MS Center at Texas Neurology, Dallas

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00784836 - Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients | Biotech Hunter | Biotech Hunter